Home > Dermatology > AAD 2022 > New Developments and Unmet Needs in Dermatology > Light at the end of the tunnel for vitiligo therapy

Light at the end of the tunnel for vitiligo therapy

Presented By
Dr David Rosmarin, Tufts Medical Center, USA
Presented by
David Rosmarin
AAD 2022
Phase 3, TRuE-V1; TRuE-V2
There is a great need for novel therapies for vitiligo, as available treatment modalities have only shown limited efficacy. Promising results are now emerging for both a local and a systemic JAK inhibitor in this difficult-to-treat disease. Ruxolitinib cream showed long-term efficacy in 2 phase 3 trials with patients achieving substantial repigmentation, and the oral ritlecitinib showed efficacy over 48 weeks in a phase 2b trial. The disease pathogenesis of vitiligo is largely regulated by IFN-γ activation and subsequent Janus kinase (JAK) signalling pathway, providing a rationale to target JAK proteins for this indication (see Box). The JAK1/JAK2 inhibitor ruxolitinib in a cream formulation has demonstrated substantial repigmentation over 52 weeks in a previous phase 2 trial [1]. In the 2 randomised, phase 3 studies TRuE-V1 (NCT04052425) and TRuE-V2 (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on